Two novel small-molecule inhibitors targeting HIF2α (PT2385 and PT2977) have been evaluated in phase 1 trials in advanced clear cell renal cell carcinoma and other solid tumors [122, 123]; however, their activities against HCC cells need to be examined. The gene discussed is EPAS1; the disease is hepatocellular carcinoma.